Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Head Sees Strong Upside To Ranbaxy Buy

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo shrugs off the cost of buying India's Ranbaxy Laboratories and says it is confident the merger of the two companies will establish a working synergy. The Japanese firm had to write off a big loss of 2008 profits, but President Takashi Shoda says he expects the purchase eventually to negate the loss. Takashi Shoda said the Ranbaxy purchase was akin to sowing a seed that would grow into a 2015 operating profit margin of 25 percent. But whether Daiichi Sankyo reaches that goal depends on its ability to keep its focus on its traditional development of new drugs rather than the generics produced by Ranbaxy. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070001

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel